LSIF becomes a major shareholder in Prostatype Genomics

Yesterday, Prostatype Genomics AB announced the good result of the rights issue carried out to finance the ongoing study in the US to be completed shortly and for commercial activities until the company is expected to receive approval from Medicare towards the end of this year. As the lead guarantor in the rights issue, LSIF has become a major shareholder in Prostatype Genomics AB, which is fully aligned with our intention as guarantor, and we are exited to be on board for the journey ahead of the company. We intend to provide stability and staying on as a major shareholder in close contact with the management. We also want to take the opportunity to thank Gemstone Capital A/S for a well arranged financing for Prostatype Genomics AB